

ASX Announcement

11 July 2025

OncoSil Medical announces appointment of Non-Executive Director

Sydney, Australia – 11 July 2025: Pancreatic cancer treatment device company **OncoSil Medical Limited (ASX:OSL)** (“OncoSil” or “the Company”) is pleased to announce the appointment of Dr Thomas Duthy as a Non-Executive Director, effective 11 July 2025.

Dr Duthy brings more than 21 years of experience across financial markets, corporate development, and board-level roles in the healthcare and life sciences sectors. He was previously Head of Corporate Development and Investor Relations at Sirtex Medical (ASX:SRX), where he played a key role in its \$1.9 billion acquisition, the largest medical device transaction in Australian history.

Dr Duthy is the Founder and Director of Nemean Group, a corporate advisory firm serving healthcare and technology companies, and has been involved in numerous successful M&A transactions. He currently advises Mayne Pharma (ASX:MYX) and serves as a Non-Executive Director of Invex Therapeutics (ASX:IXC). Dr Duthy holds a PhD from the University of Adelaide and an MBA from Deakin University.

In conjunction with this appointment, Dr Gabriel Liberatore has resigned from the OncoSil Board of Directors for personal reasons, effective 11 July 2025. The Board extends its sincere thanks to Dr Liberatore for his valuable contribution and dedicated service to OncoSil Medical and warmly welcomes Dr Thomas Duthy to the Board.

Thomas Duthy, said:

"I am pleased to be joining the Board of OncoSil Medical at this pivotal time, as the Company builds strong clinical momentum through its PANCOSIL and TRIPP-FFX trials, while expanding its treatment footprint across Europe. To align with our supportive shareholders, I have requested and received consent from the Board to be issued Oncosil shares at \$1.50, following shareholder approval (representing a 25% premium to the recent capital raising price), in lieu of the entire first year of Director fees that would otherwise accrue as a Non-Executive Director of Oncosil and noting these shares will be voluntarily escrowed for 12 months from my appointment to the Board. I look forward to working with the Board and management team to drive continued clinical success, market expansion and adoption and to deliver transformative outcomes for patients living with unresectable locally advanced pancreatic cancer."

Nigel Lange, CEO & Managing Director of OncoSil Medical, said:

"We're delighted to welcome Dr Thomas Duthy to the Board at a time of strong clinical progress and growing commercial traction. His depth of experience in capital markets and strategic transactions in the healthcare sector will be invaluable as we continue to scale our global presence and drive shareholder value."

Douglas Cubbin, Chairman of OncoSil Medical, said:

"On behalf of the Board, I would like to sincerely thank Gabriel for his counsel and commitment to OncoSil, and we wish him all the very best. We are delighted to welcome Thomas to the Board, his deep sector knowledge and capital markets expertise will be invaluable as we continue to execute on our strategy."

Authorisation & Additional Information

This announcement was authorised by the Chairman of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043	Mr. Nathan Jong Company Secretary E: Nathan.Jong@acclime.com T: +61 3 9864 4810	Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 7257 7338
--	--	---

About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival¹.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (³²P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient's pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: www.oncosil.com/

References: 1. <https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/>